{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:53:22Z","timestamp":1781650402040,"version":"3.54.5"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"HKUMed Research Collaboration Booster Fund"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Migraine is a highly prevalent neurological disorder and one of the leading causes of disability worldwide. Despite this immense public health impact, real-world utilization of migraine-specific pharmacotherapies across different income levels remains poorly characterized. This study examines longitudinal consumption trends of migraine-specific medications (MSMs) across 73 countries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using the IQVIA-MIDAS database, region\/country-level quarterly sales volumes of specific MSMs and propranolol from 2015 to 2024 were extracted and normalized to standard units per 1000 population. Descriptive statistics were summarized using the median, interquartile range (IQR), population-weighted mean and standard error (SE). For stratified analysis, the 73 countries were classified into high-, upper-middle-, and lower-middle-income countries (HICs, UMICs, LMICs). Temporal trends were evaluated using joinpoint regression to calculate the annual percent change (APC). Multiple intervention interrupted time series (ITS) models assessed the sequential impacts of CGRP introduction (May 2018) and the COVID-19 pandemic (January 2020).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between 2015 and 2024, median consumption of all MSMs nearly doubled from 101.77 to 194.39, with population-weighted averages rising from 149.23 to 201.05. The MSM consumption was overwhelmingly concentrated in HICs (337.11 to 378.13), while consumption in UMICs (9.40 to 15.10) and LMICs (18.77 to 28.01) remained persistently low. Acute MSMs, mainly triptans, drove most consumption and showed accelerating growth. Preventive MSM consumption initially declined before rebounding, largely from rapid uptake of CGRP inhibitors in HICs. Propranolol remained the most consistently consumed preventive agent across all income groups. The COVID-19 pandemic coincided with a temporary drop in MSM consumption followed by accelerated long-term growth in several groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>MSM consumption remains markedly unequal and heavily concentrated in HICs. The advanced CGRP inhibitors represent an important therapeutic advance, while underlying gaps in migraine-specific preventive pharmacotherapy largely unresolved. Addressing these global disparities requires healthcare prioritization aligned with the actual disability weight of migraine.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s10194-026-02363-6","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T07:55:21Z","timestamp":1776239721000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Trends in migraine-specific medication consumption: a multinational analysis of 73 countries based on IQVIA-MIDAS database, 2015 to 2024"],"prefix":"10.1186","volume":"27","author":[{"given":"Cuiling","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiwen","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxin","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinya","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel Yui Ki","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian Chi Kei","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther Wai Yin","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Tsz Tsun","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"issue":"5","key":"2363_CR1","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/S1474-4422(18)30085-1","volume":"17","author":"J Olesen","year":"2018","unstructured":"Olesen J (2018) International classification of headache disorders. Lancet Neurol 17(5):396\u2013397","journal-title":"Lancet Neurol"},{"key":"2363_CR2","doi-asserted-by":"publisher","first-page":"800605","DOI":"10.3389\/fneur.2021.800605","volume":"12","author":"P Amiri","year":"2022","unstructured":"Amiri P, Kazeminasab S, Nejadghaderi SA et al (2022) Migraine: a review on its history, global epidemiology, risk factors, and comorbidities. Front Neurol 12:800605","journal-title":"Front Neurol"},{"issue":"1","key":"2363_CR3","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s10194-025-02164-3","volume":"26","author":"Z He","year":"2025","unstructured":"He Z, Zhang Q, Sun Y, Yang J, Zhao M (2025) Migraine and risk of all-cause mortality and specific cause mortality: a systematic review and meta-analysis. J Headache Pain 26(1):223","journal-title":"J Headache Pain"},{"issue":"1","key":"2363_CR4","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/S1474-4422(11)70266-6","volume":"11","author":"T Kurth","year":"2012","unstructured":"Kurth T, Chabriat H, Bousser M-G (2012) Migraine and stroke: a complex association with clinical implications. Lancet Neurol 11(1):92\u2013100","journal-title":"Lancet Neurol"},{"issue":"3","key":"2363_CR5","doi-asserted-by":"publisher","first-page":"e020498","DOI":"10.1136\/bmjopen-2017-020498","volume":"8","author":"AN Mahmoud","year":"2018","unstructured":"Mahmoud AN, Mentias A, Elgendy AY et al (2018) Migraine and the risk of cardiovascular and cerebrovascular events: a meta-analysis of 16 cohort studies including 1 152 407 subjects. BMJ open 8(3):e020498","journal-title":"BMJ open"},{"issue":"1","key":"2363_CR6","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13561-023-00459-2","volume":"13","author":"A Eltrafi","year":"2023","unstructured":"Eltrafi A, Shrestha S, Ahmed A, Mistry H, Paudyal V, Khanal S (2023) Economic burden of chronic migraine in OECD countries: a systematic review. Health Econ Rev 13(1):43","journal-title":"Health Econ Rev"},{"issue":"3","key":"2363_CR7","doi-asserted-by":"publisher","first-page":"231","DOI":"10.2165\/00019053-200119030-00002","volume":"19","author":"P Stang","year":"2001","unstructured":"Stang P, Cady R, Batenhorst A, Hoffman L (2001) Workplace productivity: a review of the impact of migraine and its treatment. PharmacoEconomics 19(3):231\u2013244","journal-title":"PharmacoEconomics"},{"key":"2363_CR8","doi-asserted-by":"crossref","unstructured":"Buse DC, Rupnow MF, Lipton RB (2009) Assessing and managing all aspects of migraine: migraine attacks, migraine-related functional impairment, common comorbidities, and quality of life. Elsevier 422\u2013435","DOI":"10.4065\/84.5.422"},{"key":"2363_CR9","unstructured":"Organization WH (2025) Global status report on neurology. World Health Organization"},{"issue":"12","key":"2363_CR10","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/S1474-4422(25)00402-8","volume":"24","author":"AK Hus","year":"2025","unstructured":"Hus AK, Xu YY, Steinmetz JD et al (2025) Global, regional, and national burden of headache disorders, 1990\u20132023: a systematic analysis for the Global Burden of Disease Study 2023. Lancet Neurol 24(12):1005\u20131015","journal-title":"Lancet Neurol"},{"issue":"8","key":"2363_CR11","doi-asserted-by":"publisher","first-page":"033310242412526","DOI":"10.1177\/03331024241252666","volume":"44","author":"F Puledda","year":"2024","unstructured":"Puledda F, Sacco S, Diener H-C et al (2024) International Headache Society global practice recommendations for the acute pharmacological treatment of migraine. Cephalalgia 44(8):03331024241252666","journal-title":"Cephalalgia"},{"issue":"8","key":"2363_CR12","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41582-021-00509-5","volume":"17","author":"AK Eigenbrodt","year":"2021","unstructured":"Eigenbrodt AK, Ashina H, Khan S et al (2021) Diagnosis and management of migraine in ten steps. Nat Reviews Neurol 17(8):501\u2013514","journal-title":"Nat Reviews Neurol"},{"issue":"6","key":"2363_CR13","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/ncn3.70042","volume":"13","author":"N Araki","year":"2025","unstructured":"Araki N, Takeshima T, Igarashi H et al (2025) Clinical practice guideline for headache disorders 2021. Neurol Clin Neurosci 13(6):389\u2013407","journal-title":"Neurol Clin Neurosci"},{"issue":"9","key":"2363_CR14","doi-asserted-by":"publisher","first-page":"333102424126973","DOI":"10.1177\/03331024241269735","volume":"44","author":"F Puledda","year":"2024","unstructured":"Puledda F, Sacco S, Diener HC et al (2024) International Headache Society Global Practice Recommendations for Preventive Pharmacological Treatment of Migraine. Cephalalgia Sep 44(9):3331024241269735. https:\/\/doi.org\/10.1177\/03331024241269735","journal-title":"Cephalalgia Sep"},{"issue":"4","key":"2363_CR15","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/head.14692","volume":"64","author":"AC Charles","year":"2024","unstructured":"Charles AC, Digre KB, Goadsby PJ et al (2024) Calcitonin gene-related peptide\u2010targeting therapies are a first\u2010line option for the prevention of migraine: an American Headache Society position statement update. Headache: J Head Face Pain 64(4):333\u2013341","journal-title":"Headache: J Head Face Pain"},{"issue":"2","key":"2363_CR16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.17712\/nsj.2025.2.20240097","volume":"30","author":"FA Al-Suwaidan","year":"2025","unstructured":"Al-Suwaidan FA, Almudaiheem HY, Alotaibi HF et al (2025) Saudi clinical practice guidelines for the treatment and prevention of migraine headache. Neurosciences J 30(2):77\u201391","journal-title":"Neurosciences J"},{"issue":"9","key":"2363_CR17","doi-asserted-by":"publisher","first-page":"105501","DOI":"10.1016\/j.nurpra.2025.105501","volume":"21","author":"MT El Hussein","year":"2025","unstructured":"El Hussein MT, Fraser L (2025) Pharmacologic Management of Migraine in Primary Care: Nurse Practitioner Guide. J Nurse Practitioners 21(9):105501","journal-title":"J Nurse Practitioners"},{"issue":"1","key":"2363_CR18","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12883-024-03600-8","volume":"24","author":"P Pozo-Rosich","year":"2024","unstructured":"Pozo-Rosich P, Carmo M, Mu\u00f1iz A, Armada B, Moya-Alarc\u00f3n C, Pascual J (2024) Migraine treatment: quo vadis? Real-world data study (2015\u20132022) in Spain. BMC Neurol 24(1):107","journal-title":"BMC Neurol"},{"issue":"8","key":"2363_CR19","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1080\/03007995.2025.2552277","volume":"41","author":"T Takeshima","year":"2025","unstructured":"Takeshima T, Ahmadyar G, Duan M, Yamazaki T, Inoue S, Nishimura C (2025) Real world treatment patterns and unmet needs of migraine preventive treatments in Japan: JMDC claims analysis. Curr Med Res Opin 41(8):1559\u20131571","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"2363_CR20","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1080\/13696998.2023.2207413","volume":"26","author":"C Gaul","year":"2023","unstructured":"Gaul C, Seidel K, Heuck A et al (2023) Real-world treatment patterns and healthcare resource utilization among migraine patients: a German claims database analysis. J Med Econ 26(1):667\u2013678","journal-title":"J Med Econ"},{"issue":"1","key":"2363_CR21","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s10194-022-01413-z","volume":"23","author":"LJ Krasenbaum","year":"2022","unstructured":"Krasenbaum LJ, Pedarla VL, Thompson SF, Tangirala K, Cohen JM, Driessen MT (2022) A real-world study of acute and preventive medication use, adherence, and persistence in patients prescribed fremanezumab in the United States. J Headache Pain 23(1):54","journal-title":"J Headache Pain"},{"issue":"11","key":"2363_CR22","doi-asserted-by":"publisher","first-page":"e038972","DOI":"10.1136\/bmjopen-2020-038972","volume":"10","author":"V Orlando","year":"2020","unstructured":"Orlando V, Mucherino S, Monetti VM, Trama U, Menditto E (2020) Treatment patterns and medication adherence among newly diagnosed patients with migraine: a drug utilisation study. BMJ open 10(11):e038972","journal-title":"BMJ open"},{"issue":"5","key":"2363_CR23","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/head.14721","volume":"64","author":"DC Buse","year":"2024","unstructured":"Buse DC, Sakai F, Matharu M et al (2024) Characterizing gaps in the preventive pharmacologic treatment of migraine: Multi-country results from the CaMEO\u2010I study. Headache: J Head Face Pain 64(5):469\u2013481","journal-title":"Headache: J Head Face Pain"},{"key":"2363_CR24","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez-Bravo\u2010Rodrigo J, Pascual\u2010Morena C, Saz\u2010Lara A. et al (2025) Real\u2010world effectiveness and safety of galcanezumab for the treatment of migraine: A systematic review and meta\u2010analysis. Headache: J Head Face Pain","DOI":"10.1111\/head.70003"},{"issue":"1","key":"2363_CR25","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s10194-024-01753-y","volume":"25","author":"R Oliveira","year":"2024","unstructured":"Oliveira R, Gil-Gouveia R, Puledda F (2024) CGRP-targeted medication in chronic migraine-systematic review. J Headache Pain 25(1):51","journal-title":"J Headache Pain"},{"issue":"1","key":"2363_CR26","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s10194-022-01476-y","volume":"23","author":"JL Nguyen","year":"2022","unstructured":"Nguyen JL, Munshi K, Peasah SK et al (2022) Trends in utilization and costs of migraine medications, 2017\u20132020. J Headache Pain 23(1):111","journal-title":"J Headache Pain"},{"key":"2363_CR27","doi-asserted-by":"crossref","unstructured":"Ott J, World Bank World Development Indicators (2024) Encyclopedia of quality of life and well-being research. Springer 7858\u20137858","DOI":"10.1007\/978-3-031-17299-1_3278"},{"key":"2363_CR28","unstructured":"World Bank Country and lending groups. World bank country and lending groups \u2013 world bank data help desk. Accessed March 12 (2026) https:\/\/datahelpdesk.worldbank.org\/knowledgebase\/articles\/906519-world-bank-country-and-lending-groups"},{"key":"2363_CR29","unstructured":"Who model lists of essential medicines. World Health Organization. Accessed March 12 (2026) https:\/\/www.who.int\/groups\/expert-committee-on-selection-and-use-of-essential-medicines\/essential-medicines-lists."},{"key":"2363_CR30","first-page":"79","volume":"78","author":"JR Graham","year":"1967","unstructured":"Graham JR (1967) Cardiac and pulmonary fibrosis during methysergide therapy for headache. Trans Am Clin Climatol Assoc 78:79","journal-title":"Trans Am Clin Climatol Assoc"},{"issue":"5","key":"2363_CR31","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1002\/pds.5606","volume":"32","author":"JM Hincapie-Castillo","year":"2023","unstructured":"Hincapie-Castillo JM, Goodin A (2023) Using Joinpoint regression for drug utilization research: Tutorial and case study of prescription opioid use in the United States. Pharmacoepidemiol Drug Saf 32(5):509\u2013516","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"2363_CR32","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1111\/jep.13266","volume":"26","author":"B Zhang","year":"2020","unstructured":"Zhang B, Liu W, Lemon SC et al (2020) Design, analysis, power, and sample size calculation for three-phase interrupted time series analysis in evaluation of health policy interventions. J Eval Clin Pract 26(3):826\u2013841","journal-title":"J Eval Clin Pract"},{"issue":"11","key":"2363_CR33","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1007\/s40265-018-0944-0","volume":"78","author":"A Markham","year":"2018","unstructured":"Markham A, Erenumab (2018) First Global Approval: A. Markham. Drugs 78(11):1157\u20131161","journal-title":"Drugs"},{"key":"2363_CR34","doi-asserted-by":"crossref","unstructured":"Thakur K, Tablante E, Harper M, Shakir R, Bergen D, Dua T, (2015). The world health organization atlas: country resources for neurological disorders (PL01. 001). Neurology. 2016;86(16):PL01. 001","DOI":"10.1212\/WNL.86.16_supplement.PL01.001"},{"issue":"3","key":"2363_CR35","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/ene.14098","volume":"27","author":"M Viana","year":"2020","unstructured":"Viana M, Khaliq F, Zecca C et al (2020) Poor patient awareness and frequent misdiagnosis of migraine: findings from a large transcontinental cohort. Eur J Neurol 27(3):536\u2013541","journal-title":"Eur J Neurol"},{"key":"2363_CR36","unstructured":"Kingston WS, Halker R (2017) Determinants of suboptimal migraine diagnosis and treatment in the primary care setting. J Clin Outcomes Manage. 24(7)"},{"key":"2363_CR37","doi-asserted-by":"publisher","first-page":"100427","DOI":"10.1016\/j.ensci.2022.100427","volume":"29","author":"D Mortel","year":"2022","unstructured":"Mortel D, Kawatu N, Steiner TJ, Saylor D (2022) Barriers to headache care in low-and middle-income countries. Eneurologicalsci 29:100427","journal-title":"Eneurologicalsci"},{"issue":"3","key":"2363_CR38","doi-asserted-by":"publisher","first-page":"216","DOI":"10.4103\/ijp.ijp_783_20","volume":"54","author":"P Thangaraju","year":"2022","unstructured":"Thangaraju P, Mahesh K, Venkatesan S (2022) Information on migraine drugs in commonly available Indian drug information sources\u2013Whether we satisfied the community needs? Indian J Pharmacol 54(3):216\u2013220","journal-title":"Indian J Pharmacol"},{"key":"2363_CR39","doi-asserted-by":"publisher","first-page":"251581632514155","DOI":"10.1177\/25158163251415565","volume":"9","author":"J Duncan","year":"2026","unstructured":"Duncan J, Gowrie-Sankar S, Mohammed SR, Ali A, Panday A (2026) Management of migraine in the Caribbean: A descriptive study. Cephalalgia Rep 9:25158163251415565","journal-title":"Cephalalgia Rep"},{"issue":"10013","key":"2363_CR40","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0140-6736(15)00469-9","volume":"387","author":"R Khatib","year":"2016","unstructured":"Khatib R, McKee M, Shannon H et al (2016) Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data. Lancet 387(10013):61\u201369","journal-title":"Lancet"},{"issue":"5","key":"2363_CR41","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1111\/head.14693","volume":"64","author":"J Robblee","year":"2024","unstructured":"Robblee J, Hakim SM, Reynolds JM, Monteith TS, Zhang N, Barad M (2024) Nonspecific oral medications versus anti\u2013calcitonin gene-related peptide monoclonal antibodies for migraine: A systematic review and meta\u2010analysis of randomized controlled trials. Headache: J Head Face Pain 64(5):547\u2013572","journal-title":"Headache: J Head Face Pain"},{"issue":"12","key":"2363_CR42","doi-asserted-by":"publisher","first-page":"915","DOI":"10.31128\/AJGP-01-21-5807","volume":"50","author":"JC Ray","year":"2021","unstructured":"Ray JC, Macindoe C, Ginevra M, Hutton EJ (2021) The state of migraine:\u2018An update on current and emerging treatments\u2019. Australian J Gen Pract 50(12):915\u2013921","journal-title":"Australian J Gen Pract"},{"issue":"1","key":"2363_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/head.13456","volume":"59","author":"AH Society","year":"2019","unstructured":"Society AH (2019) The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache: J Head Face Pain 59(1):1\u201318","journal-title":"Headache: J Head Face Pain"},{"key":"2363_CR44","doi-asserted-by":"crossref","unstructured":"Woldeamanuel YW, de Oliveira AB (2026) Merging economic issues and social need: a call to action for headache disorders in the sustainable development goals era. migraine and headache disorders: the global perspective. Springer 115\u2013126.","DOI":"10.1007\/978-3-032-14609-0_10"},{"issue":"3","key":"2363_CR45","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1093\/eurpub\/ckab047","volume":"31","author":"CM Roy","year":"2021","unstructured":"Roy CM, Bollman EB, Carson LM, Northrop AJ, Jackson EF, Moresky RT (2021) Assessing the indirect effects of COVID-19 on healthcare delivery, utilization and health outcomes: a scoping review. Eur J Pub Health 31(3):634\u2013640","journal-title":"Eur J Pub Health"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-026-02363-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-026-02363-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-026-02363-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:04:59Z","timestamp":1781647499000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s10194-026-02363-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2363"],"URL":"https:\/\/doi.org\/10.1186\/s10194-026-02363-6","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"assertion":[{"value":"26 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"145"}}